7876 Share Price Performance
NT$39.70
-3.50 (-8.10%)
Price NT$39.70
Share Pricen/a
No recently updated narratives available.
Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan.